a new investigator-sponsored trial treating patients who are in remission with ovarian, fallopian tube, or primary peritoneal cancer, using Incyte's IDO1 inhibitor INCB 24360 in combination with Celldex's CDX-1401, a DEC-205/NY-ESO-1 fusion protein, and the adjuvant Poly ICLC. The trial is not yet recruiting and will be conducted at the Roswell Park Cancer Institute in Buffalo, NY.
Pleasant as it is to see, the business significance is probably low. As HH recently pointed out, the value of these exploratory trials of '360 is in determining if it's really a drug candidate. It is. The business issue is how to get it onto the market. One possible way was to show that it was easy to use and consistently beneficial. That's pretty much off the board. So there'll have to be at least one formal p3 with a specific protocol and a well-defined target.